The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors.

Presentation Details:

Title: GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model

Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS

Abstract code: EXTH-31

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E

Title: Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma

Presenter: Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine

Abstract code: CTNI-25

Format: Poster presentation

Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST

Location: Pennsylvania Convention Center, Exhibit Halls D and E